Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers studied people taking Truvada as PrEP and plan to conduct similar research on newer antiretrovirals.
Gilead Sciences presented findings from several studies of the single-tablet antiretroviral regimen at a recent scientific meeting.
Teva’s new version of TDF and emtricitabine doesn’t offer much of a price break, but that could come next spring.
The finding from a 2018 survey raises concerns that men are accessing PrEP without receiving the recommended medical monitoring.
This bureaucratic requirement may frustrate access to PrEP in the U.S. region where the HIV epidemic is the most severe.
A handful of such cases have been reported since Truvada was approved as pre-exposure prophylaxis in 2012.
Total payments for the HIV prevention pill exceeded $2 billion in 2018.
Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.
This finding calls into question research that has projected that frequent testing among men on PrEP could drive down STI rates.
A study found that men who started PrEP a week before a vacation and stopped a week after coming home adhered well to the daily regimen.
A low-cost generic version of Truvada as PrEP will hit the market September 30.
The 2-1-1 HIV prevention regimen offers an option for those who don’t want to take daily pills.
Cabotegravir injections given every eight weeks as PrEP are even more effective than daily Truvada.
The HIV advocacy group has been assiduously tracking PrEP data for five years.
The SEARCH study included men and women at elevated risk of HIV in Kenya and Uganda.
The placebo-controlled trial compared injections of cabotegravir given every eight weeks versus daily Truvada as PrEP.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.